Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

Atopic Dermatitis

The approved labeling for topical ruxalitinib includes a warning where they're suggesting that it may not be used in patients that are on systemic immunosuppressive agents or biologic agents that are used for atopic dermatitis. Remember that the label there are no contraindications to the use of topical ruxalitinib. The reason why this is in the package insert is because this was not studied in reality. I have used topical ruxalitinib in patients treated with topiliumab and traloquinumab. Remember, these are very effective systemic biologic agents, but patients have a chronic disease and are going to have some breakthrough lesions. So a topical therapy, especially a non steroidal agent, if it has to be used over a more prolific period of time, is welcome. And knowing that depiliumab and trallicinumab are immunomodulators, not really immunosuppressive agents, there really is nothing additional that we have to be concerned about. In my mind and based on the literature, if we're utilizing topical roxylitinib in those patients.

Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

Related CME